Proton pump inhibitors combined with a certain chemotherapy drug may lower the possibility for cancer patients to recover and survive.
Oncology
Advertisement
Top news of the day from across the health care landscape.
Advertisement
Scientists have developed a new tool to test current strategies for finding mutant gene cancer drivers.
Regular use of over-the-counter, anti-inflammatory drugs associated with an increased risk of death in patients with cancer.
Regular use of over-the-counter, anti-inflammatory drugs associated with an increased risk of death in patients with cancer.
Investigative drug may improve overall survival and reduce chemotherapy-induced heart damage in children with acute myelogenous leukemia.
Advertisement
Cisplatin used in combination with sodium thiosulfate significantly reduced the incidence of hearing loss in pediatric cancer patients.
Study finds link between aspirin and blood platelets in cancer cells.
Patients with relapsed diffuse large-B cell lymphoma had monthly healthcare costs of $6566.
Progression free survival more than doubled with niraparib treatment.
Advertisement
Niraparib is an investigational PARP inhibitor currently being evaluated for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Metastasis affects as many as 5% of cancer patients around the world.
Top news of the day from across the health care landscape.
Cyclin-dependent kinase inhibitor reduces Ki67 expression and shows promise in breast cancer treatment.
Agreement will expand treatment options for patients with hepatitis C.
Rubraca is the latest targeted agent that treats cancers caused by specific mutations in a patient’s gene.
FDA grants accelerated approval for rucaparib (Rubraca) to treat advanced ovarian cancer.
Pembrolizumab was associated with clinically meaningful improvements in quality of life over chemotherapy.
Researchers discovered a statistically significant link between diabetes and all-cause mortality.
Top news of the day from across the health care landscape.
Top news of the week in oncology and cancer drug development.
Rates of suicide elevated in cancer survivors diagnosed before the age of 25 years.
The biosimilar epoetin was well-tolerated in elderly cancer patient populations.
Xtandi plus abiraterone acetate and prednisone fails to improve progression-free survival in prostate cancer.
Ceritinib (Zykadia) could potentially be used as a first-line treatment in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.
Attacking lung cancer cell foundation may present effective treatment option.
New findings may lead to therapeutic options for stopping lung cancer cells from spreading to different parts of the body.
Sofosbuvir/ribavirin treatment is typically prescribed for 12 weeks, but for some patients with hepatitis C virus, a longer duration may be needed.
Zykadia more than doubled progression-free survival in patients with ALK+ non-small cell lung cancer.
Treatment with Tecentriq helps successfully clear advanced lung cancer.
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Pharmacists Can Close the Opioid Addiction Care Gap
2
US Measles Cases Climb, Raising Questions About Preparedness and Prevention
3
FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma
4
FDA Approval Signals Broader Recognition of Sexual Health in Aging Women
5
